-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $16

Benzinga·01/20/2026 15:15:48
Listen to the news
JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Neutral and lowers the price target from $17 to $16.